| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 193.52 | 11.9% | 13.1% |
| Total Income | 204.30 | 10.8% | 11.3% |
| Expenditure | 207.63 | 21.7% | 1.6% |
| PBT | -3.33 | 124.3% | 112.9% |
| Net Profit | -5.72 | 138.4% | 121.0% |
| OPM | -0.76% | 8.96pp | 3.65pp |
| NPM | -2.80% | 10.89pp | 14.05pp |
| EPS | 1.13 | 61.6% | 79.0% |
Orchid Pharma Reports Q-2 & Half Year Results for 2025 with 20.99% EPS Growth
11 Nov 2025 · 11 Nov 2025, 03:31 pm
Summary
Orchid Pharma Ltd. has reported its Q-2 and half year results for 2025. The company has shown a growth of 20.99% in EPS. The financial results are unaudited and the revenue stands at 92,192.59 lakhs for the half year ended on September 30, 2025.
Key Highlights
- 1
Q-2 and half year results for 2025 reported
- 2
Unaudited financial results
- 3
Revenue for half year ended on September 30, 2025: 92,192.59 lakhs
- 4
EPS growth: 20.99%
Management Comments
N
Not provided
Not provided
Informational and educational content only. Not investment advice.